Compare
Ceribell, Inc. vs Vaso Corp vs Biolife Solutions Inc vs Electromed, Inc.
| Latest fiscal year | Ceribell, Inc. CBLL | Vaso Corp VASO | Biolife Solutions Inc BLFS | Electromed, Inc. ELMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $89.06M | $89.10M | $96.21M | $73.78M |
| Revenue growth (YoY) | +36.1% | +2.7% | +28.9% | +15.3% |
| Gross margin | 87.9% | 61.4% | 64.6% | 78.5% |
| Operating margin | -65.6% | -3.2% | -17.3% | 18.8% |
| Net margin | -60.0% | 1.8% | -4.8% | 15.3% |
| Net income | -$53.41M | $1.57M | -$4.59M | $11.30M |
| EPS (Diluted) | -$1.46 | $0.01 | -$0.10 | $1.30 |
| Operating cash flow | -$40.81M | $9.27M | $20.11M | $9.66M |
| Free cash flow | -$41.58M | n/a | $10.64M | $8.41M |
| Cash & equivalents | $40.48M | $35.05M | $33.04M | $20.45M |
| Total assets | $195.80M | $88.35M | $405.88M | $66.27M |
| Total liabilities | $40.47M | n/a | $34.00M | $12.29M |
| Shareholders' equity | $155.34M | $29.43M | $371.89M | $53.98M |
| Return on year-end equity | -34.4% | 5.3% | -1.2% | 20.9% |
| Shares outstanding | 37.49M | 175.95M | 48.20M | 8.37M |
Revenue, most recent five fiscal years
| Fiscal year | Ceribell, Inc. | Vaso Corp | Biolife Solutions Inc | Electromed, Inc. |
|---|---|---|---|---|
| Latest | $89.06M Ended 2025-12-31 | $89.10M Ended 2025-12-31 | $96.21M Ended 2025-12-31 | $73.78M Ended 2026-06-30 |
| 1 year earlier | $65.44M Ended 2024-12-31 | $86.77M Ended 2024-12-31 | $74.65M Ended 2024-12-31 | $64.00M Ended 2025-06-30 |
| 2 years earlier | $45.23M Ended 2023-12-31 | $81.02M Ended 2023-12-31 | $68.02M Ended 2023-12-31 | $54.72M Ended 2024-06-30 |
| 3 years earlier | n/a | $79.29M Ended 2022-12-31 | $76.24M Ended 2022-12-31 | $48.07M Ended 2023-06-30 |
| 4 years earlier | n/a | $75.58M Ended 2021-12-31 | $119.16M Ended 2021-12-31 | $41.66M Ended 2022-06-30 |